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Abstract
Bisphosphonates represent the gold-standard pharmaceutical agent for reducing fracture risk. 
Long-term treatment with bisphosphonates can result in tissue brittleness which in rare clinical 
cases manifests as atypical femoral fracture. Although this has led to an increasing call for 
bisphosphonate cessation, few studies have investigated therapeutic options for follow-up 
treatment. The goal of this study was to test the hypothesis that treatment with raloxifene, a drug 
that has cell-independent effects on bone mechanical material properties, could reverse the 
compromised mechanical properties that occur following zoledronate treatment. Skeletally mature 
male C57Bl/6J mice were treated with vehicle (VEH), zoledronate (ZOL), or ZOL followed by 
raloxifene (RAL; 2 different doses). At the conclusion of 8 weeks of treatment femora were 
collected and assessed with microCT and mechanical testing. Trabecular BV/TV was significantly 
higher in all treated animals compared to VEH with both RAL groups having significantly higher 
BV/TV compared to ZOL (+21%). All three drug-treated groups had significantly more cortical 
bone area, higher cortical thickness, and greater moment of inertia at the femoral mid-diaphysis 
compared to VEH with no difference among the three treated groups. All three drug-treated 
groups had significantly higher ultimate load compared to VEH-treated animals (+14 to 18%). 
Both doses of RAL resulted in significantly higher displacement values compared to ZOL-treated 
animals (+25 to +50%). In conclusion, the current work shows beneficial effects of raloxifene in 
animals previously treated with zoledronate. The higher mechanical properties of raloxifene-
treated animals, combined with similar cortical bone geometry compared to animals treated with 
zoledronate, suggest the raloxifene treatment is enhancing mechanical material properties of the 
tissue.
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INTRODUCTION
Over the past few decades, bisphosphonates have represented the gold-standard 
pharmaceutical agent for reducing fracture risk in osteoporosis as well a number of other 
metabolic conditions that induce skeletal fragility [1,2]. Their potent anti-remodeling effect 
slows bone loss and thereby stabilizes overall mechanical competence and reduces fracture. 
The benefits of remodeling suppression, however, are not without cost.
Remodeling serves an important function to the skeleton in the form of removing regions of 
tissue that are damaged, are void of viable cells, or have tissue-level properties that are 
suboptimal. Suppression of remodeling with bisphosphonates has been shown to allow 
microdamage accumulation [3], permit increased regions of non-viable osteocytes [4], and 
lead to bone that has higher mineralization and non-enzymatic collagen cross-linking [5–7]. 
These changes are associated with compromised tissue-level mechanical properties [8,9]. 
Clinical reductions in fracture risk shows that these tissue-level changes do not outweigh the 
benefits from preservation of bone mass [10], at least in the short term. Preclinical data 
suggest, however, that with long-term treatment the tissue-level changes may be sufficient in 
some situations to at least partially negate the benefits [11,12]. An extreme example is 
atypical femoral fractures, associated with anti-remodeling treatment, that tend to occur 
when treatment extends beyond five years and are hypothesized to be caused by changes 
related to remodeling suppression [13,14]. Although atypical femoral fractures are quite 
rare, their challenging treatment makes them clinically significant.
Bisphosphonates bind to the skeleton and therefore have long-lasting effects [15]. Clinical 
data show a single dose of zoledronate retains an effect on bone resorption for well beyond 5 
years [16,17]. Although this long-lasting effect represents a positive feature of the drug [18], 
it presents a challenge from the perspective of changes to bone material properties with 
long-term remodeling suppression. Raloxifene, an FDA approved agent for reducing fracture 
risk, has recently been shown to affect material-level mechanical properties of bone through 
both cellular effects on the estrogen receptor as well as non-cellular mechanisms that affect 
hydration [19,20]. The goal of this study was to test the hypothesis that raloxifene treatment 
could reverse the compromised mechanical properties that occur following zoledronate 
treatment. To test this hypothesis, we utilized a mouse model that has previously been shown 
to manifest bisphosphonate-induced reductions in bone mechanical properties [21].
METHODS
Animals and Drug treatment
Sixteen week old C57Bl/6J male mice (n=80, from JAX laboratory) were used for this study. 
Male mice were chosen to build on previous data from our lab and others using this strain 
and sex [21–23]. Animals received a zoledronic acid (n=60; ZOL, subcutaneous injection of 
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0.06 mg/kg/body weight (BW)) or saline vehicle (n=20; VEH) at 16 weeks of age, then 
another at 20 weeks of age (Figure 1). At 20 weeks of age, animals in designated treatment 
groups received raloxifene (RAL; 5 days/week, subcutaneous injection) at one of two doses: 
low dose (0.5 mg/kg/BW (n=20; ZOL + RAL-L)) or high dose (2.0 mg/kg/BW (n=20; ZOL 
+ RAL-H)). The dose and duration of ZOL was chosen as it has shown efficacy in 
suppressing remodeling and affecting mechanical properties in this genetic strain [21]. The 
lower dose of RAL has been used previously and shown efficacy in vivo [24]; a higher dose 
was arbitrarily chosen as 4× higher to determine if dose-responses could be quantified. At 24 
weeks of age, animals were euthanized and the right femurs were removed, wrapped in 
saline-soaked gauze, and frozen (−20C) for later analysis. All procedures were approved by 
the Indiana University School of Medicine Animal Care and Use Committee prior to 
initiating the study.
μCT Imaging
Right femora were thawed and scanned with microCT (Skyscan 1176) to obtain trabecular 
and cortical bone morphology as previously described [21]. Scans were conducted using a 9 
micron voxel size. Trabecular bone was analyzed in the distal femur metaphysis (~0.5 mm 
long segment) and cortical bone was assessed at the mid-diaphysis (single slice). All scan 
reconstruction/analysis was done using manufacturer provided software. Nomenclature is 
reported in accordance with suggested guidelines [25].
Mechanical Testing
Whole bone mechanical properties were assessed in four-point bending as previously 
described [21] and in accordance with recommendations [26]. The anterior surface of each 
femur was placed on two lower supports with a span length of 9 mm and an upper span 
length of 3 mm. Specimens were loaded to failure at a rate of 2 mm/min, producing a force-
displacement curve for each sample. Using a custom MATLAB program [24], structural and 
apparent material properties were determined. Apparent material properties were derived 
using standard beam-bending equations for four-point bending and geometric data from 
microCT analyses.
Statistical Analysis
Comparisons among the four groups were made using a one-way ANOVA. When a 
significant main effect was present, post-hoc tests (pLSD) were used to determine individual 
group differences. A p value of < 0.05 was used for all determinations of significance. All 
data are presented as means +/− standard deviations.
RESULTS
There was no significant difference in baseline body mass among the groups (Table 1). 
VEH, ZOL and low dose RAL mice all gained body mass during the experiment. Final body 
mass of the low dose RAL group was significantly lower than VEH (−5%) while high dose 
RAL was significantly lower than both VEH and ZOL (−7%). There was no difference in 
femoral bone length among the groups.
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MicroCT-based assessment of trabecular and cortical morphology revealed significant 
treatment effects. Trabecular BV/TV was significantly higher in all treated animals 
compared to VEH with both RAL groups having significantly higher BV/TV compared to 
ZOL (+21%; Table 2). Higher BV/TV with treatment was the result of greater trabecular 
thickness and number. All three drug-treated groups had significantly more cortical bone 
area, higher cortical thickness, and greater moment of inertia at the femoral mid-diaphysis 
compared to VEH with no differences among the three treated groups (Table 2, Figure 2A).
All three drug-treated groups had significantly higher ultimate load compared to VEH-
treated animals (+14 to 18%; Figure 2B). While there was no significant effect of ZOL on 
total or post-yield displacement (−10% and −15%, respectively), both doses of RAL resulted 
in significantly higher displacement values compared to ZOL-treated animals (+25 to +50%; 
Figure 2C, Figure 3 and Table 3). Total work and post-yield work were significantly higher 
in both RAL groups compared to both VEH and ZOL groups. Estimates of apparent 
mechanical material properties revealed similar patterns of differences among groups with 
total strain and toughness both being significantly positively affected by RAL treatment 
compared to ZOL and VEH (Table 3).
DISCUSSION
The ability of bisphosphonates to significantly reduce fracture risk was a transformative 
milestone in the treatment of metabolic bone disease [1]. Although this drug class as a whole 
has a relatively high safety profile, there have emerged significant side effects (such as 
atypical femoral fracture and osteonecrosis of the jaw) that have been linked to treatment 
[27,28]. More specifically, the risk of these rare side effects is associated with treatment 
beyond 5–7 years. This has led to consideration of drug holidays where treatment is stopped 
for either a set period of time or until some biomarker (turnover markers or BMD) suggests 
treatment needs to be reinitiated [29]. A challenge to this approach is that bisphosphonates 
have long-lasting effects due to their binding to the skeleton, exemplified by data showing 
that after a single dose of zoledronate, bone turnover in patients is reduced for beyond 5 
years [16–18]. In many cases this is a positive and suggests that drug holidays can be 
employed without worry of rapid remodeling recovery. In other cases, such as if there is 
concern about atypical fractures, simply stopping the bisphosphonate is unlikely to be 
sufficient to change the risk profile. It is this latter scenario that is the focus of the current 
work, which asked the question of whether or not dosing with raloxifene could benefit the 
mechanical properties of bone that had been previously treated with bisphosphonate.
Bending tests of long bones, the most direct way to experimentally assess how intervention 
affects mechanical integrity, is the modality of choice and yields nearly a dozen outcome 
variables [26]. These variables provide information on how much load the bone/material can 
handle (ultimate force/ultimate stress), the bone’s/material’s resistance to bending (stiffness/
modulus) and the ability of the bone/material to deform prior to fracture (displacement/
strain). Previous work has documented that although some properties are positively affected 
(such as ultimate load), other properties such as those related to displacement/energy 
absorption, are reduced following bisphosphonate treatment (alendronate, risedronate, and 
zoledronate) [8,9,11]. Recently, we extended these findings to a mouse model, documenting 
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that 8 weeks of zoledronate treatment in C57/B6 male mice is sufficient to significantly 
reduce mechanical properties that are reflective of bone brittleness (total displacement, post-
yield displacement, and total strain) [21]. The current study was designed to build on this 
concept yet ZOL-treatment did not significantly reduce total or post-yield displacement 
(−10% and −15%, respectively). Effects in the previous study were about twice these (−25% 
in total displacement) [21]. The reason for these differences between studies is not clear but 
may simply be a function of the high variability in displacement measures (specifically post-
yield properties) from mechanical testing. It is also worth noting that we saw no difference 
between the two raloxifene doses indicating that more is not necessarily better in terms of 
enhancing mechanical properties.
Raloxifene is FDA approved for the treatment/prevention of osteoporosis but since its effects 
on bone mineral density are mild, its clinical use is modest [30]. Despite the minimal effect 
on BMD, raloxifene has been shown to significantly reduce vertebral fracture risk [31] 
raising questions as to how such modest BMD changes could reduce fracture risk [32]. 
Recently, our lab has shown that raloxifene significantly increases bone hydration and this is 
associated with improved mechanical properties, most notably post-yield parameters [19]. 
These effects have been noted both in vivo and in vitro, in mice, rats, dogs and humans 
[19,20,24,33–35]. Since at least some of the effects from raloxifene are not cell-mediated, 
we hypothesized that treatment with raloxifene could significantly benefit the mechanical 
properties of bone in conditions such as bisphosphonate-treatment where the tissue becomes 
brittle. The current work shows clear benefits of raloxifene on mechanical properties 
compared to ZOL-treatment alone. In addition, benefits of RAL were observed compared to 
ZOL-treatment in trabecular architecture. There were unexpected effects of RAL on body 
weight (most notably with the high dose) although there is no clear connection in the 
literature to such modest body weight differences explaining the effects on mechanical 
properties. Collectively, these results indicate that raloxifene has the ability to improve both 
bone mass and mechanics when administered following zoledronate therapy.
A growing number of studies have investigated combination treatment as an approach to 
treat bone disease [36]. These studies, both clinical and preclinical, are challenging to 
compare as they have utilized various combinations of agents in various orders (sequential or 
co-administration). Most studies have combined anti-resorptive (mainly bisphosphonates) 
and anabolic (mainly PTH) treatments due to their distinctly different mechanisms of action. 
One clinical study and a few preclinical studies have combined bisphosphonates with 
raloxifene, although they have done so as co-administration of drugs [37–39]. Results have 
mainly focused on BMD and biomarkers, with modest benefits of combination treatment. 
The two reports that have examined mechanics, however, both showed beneficial effects of 
co-administration compared to either monotherapy. Sequential therapy following 
bisphosphonate treatment has focused on PTH with the conceptual framework that 
stimulation of remodeling is going to be key to renewing the skeleton. Results are generally 
positive although the effects on mechanics have not been evaluated [40]. Our current results 
lend validity to a unique approach which is to target the existing bone matrix through non-
cellular mechanisms (using Raloxifene which has both cellular and non-cellular effects) to 
make it more mechanically competent while at the same time keeping remodeling low (to 
preserve bone mass).
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A key unanswered question in rodent models showing bisphosphonate-induced 
embrittlement is how these changes are occurring [21,41]. In humans and larger species 
(rabbits, dogs, non-human primates), changes in cortical bone mechanics are often attributed 
to the suppression of intracortical remodeling, resulting in the retention of older tissue that 
has higher mineralization, accumulation of collagen cross-links, and microdamage 
development [8]. The lack of normal intracortical remodeling in rodents makes this 
mechanism implausible. Rather, it suggests that bisphosphonates are having effects on the 
tissue independent of turnover suppression. We have previously documented that tissue-level 
BMD is not affected by zoledronate in this mouse model [21], leaving changes in collagen, 
or perhaps hydration, as potential aspects being directly affected by bisphosphonates.
There are several limitations to the current work. We utilized only one bisphosphonate, 
zoledronate, and thus do not know if the beneficial effects of raloxifene would occur 
following treatment with others in this drug class. We also used a single time point of 
assessment (8 weeks of dosing) and thus do not know if raloxifene could preserve 
mechanical effects following longer bisphosphonate dosing. Our study utilized male mice 
with normal bone mass, building on previous work in these mouse strains and, thus, future 
studies will need to focus on a more clinically relevant model such as ovariectomized female 
animals. Finally, we did not assess aspects of material properties (changes to collagen, 
mineral, hydration, etc.) which future work will need to do in order to understand the 
specific changes responsible for the mechanical effect.
In conclusion, the current work shows beneficial effects of raloxifene in animals previously 
treated with zoledronate. The higher ultimate load and displacement of raloxifene-treated 
animals, combined with similar cortical bone geometry compared to animals treated with 
zoledronate, suggest the raloxifene treatment is enhancing apparent mechanical material 
properties of the tissue.
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Figure 1. 
Schematic representation of study design. VEH, saline vehicle; ZOL, zoledronate; RAL, 
raloxifene. Zoledronate was given as a single injection at 16 and 20 weeks; raloxifene was 
given as a daily injection, 5 times per week, between 20 and 24 weeks.
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Figure 2. 
Structural geometry and mechanical properties of femoral diaphysis. Treatment with 
zoledronate (ZOL) or zoledronate followed by raloxifene (RAL) led to significantly more 
cortical bone (A) in the diaphysis compared to vehicle (VEH) controls. There was no 
significant difference between the three treatments relative to each other. (B) Ultimate load 
was also significantly higher in all three drug treated groups. (C) Total displacement was 
significantly higher in animals given RAL compared to those given only ZOL. P < 0.05 
versus (*) VEH or (#) ZOL.
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Figure 3. 
Schematic force-displacement curves for all groups. Error bars represent standard error of 
the mean for both load (vertical errors) and displacement (horizontal errors).
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